Welcome to our dedicated page for TMBR news (Ticker: TMBR), a resource for investors and traders seeking the latest updates and insights on TMBR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TMBR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TMBR's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Timber Pharmaceuticals announced significant progress with its lead asset, TMB-001, which has received orphan drug designation from the European Commission for two severe types of congenital ichthyosis (ARCI and XLRI). The company has achieved 50% enrollment in its Phase 3 ASCEND clinical trial, launched in June 2022, following positive FDA interactions earlier in the year. Timber also secured Breakthrough Therapy and Fast Track designations for TMB-001. Financial results showed revenues of $83,177 for 2022, a decrease from $886,532 in 2021, with approximately $9.1 million in cash at year-end. The company is exploring partnerships to fund ongoing operations.
Timber Pharmaceuticals (TMBR) has announced positive results from a sub-analysis of its Phase 2b CONTROL study of TMB-001, a topical isotretinoin for treating congenital ichthyosis (CI).
The study found significant improvements among participants with both autosomal recessive congenital ichthyosis (ARCI) and X-linked recessive ichthyosis (XLRI) in achieving primary and secondary endpoints. In the intent-to-treat population, 33% to 100% of participants with ARCI and XLRI showed a 50% reduction in Visual Index for Ichthyosis Severity (VIIS) compared to vehicle treatments.
Results support continued development of TMB-001, which has orphan designation in Europe, as a promising alternative to systemic therapies.